Overall Survival In Myelodysplastic Syndrome or Acute Myeloid Leukemia Patients Treated with On 01910.Na Correlates with Bone Marrow Blast Response.

被引：0
|
作者：
Silverman, Lewis R. [1 ]
Kaza, Azra [2 ]
Sloand, Elaine M. [3 ]
Greenberg, Peter L. [4 ]
Wilhelm, Frandois E. [5 ]
机构：
[1] Mt Sinai Sch Med, Div Hematol Oncol, New York, NY USA
[2] St Vincents Comprehens Canc Ctr, New York, NY USA
[3] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA
[4] Stanford Univ, Div Hematol, Stanford Canc Ctr, Stanford, CA 94305 USA
[5] Onconova Therapeut Inc, Newtown, PA USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1629 / 1630
页数：2
相关论文
共 50 条
  • [1] Final Phase I/II Results of Rigosertib (ON 01910.Na) Hematological Effects in Patients with Myelodysplastic Syndrome and Correlation with Overall Survival
    Raza, Azra
    Greenberg, Peter L.
    Olnes, Matthew J.
    Silverman, Lewis R.
    Wilhelm, Francois
    BLOOD, 2011, 118 (21) : 1633 - 1633
  • [2] Correlation of overall survival (OS) with bone marrow blast (BMBL) response in patients (pts) with myelodysplastic syndrome
    Silverman, Lewis R.
    Fenaux, Pierre
    Greenberg, Peter
    Demakos, Erin P.
    Santini, Valeria
    Seymour, John Francis
    Navada, Shyamala Chendal
    Petrone, Michael E.
    Snyder, Barbara R.
    Azarnia, Nozar
    Garcia-Manero, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] IMPACT OF COMORBIDITIES ON OVERALL SURVIVAL IN THE ELDERLY WITH MYELODYSPLASTIC SYNDROME OR ACUTE MYELOID LEUKEMIA TREATED BY AZACITIDINE
    Brechemier, D.
    Bertoli, S.
    Comont, T.
    Balardy, L.
    Recher, C.
    Lauwers-Cances, V.
    Beyne-Rauzy, O.
    LEUKEMIA RESEARCH, 2015, 39 : S47 - S48
  • [4] EARLY PERIPHERAL BLAST CLEARANCE CORRELATES WITH OVERALL SURVIVAL AND TIME TO RECURRENCE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
    Farina, M.
    Chiarini, M.
    Borlenghi, E.
    Serana, F.
    Cattaneo, C.
    Giustini, V.
    Passi, A.
    Pagani, C.
    Lamorgese, C.
    Roccaro, A.
    Imberti, L.
    Rossi, G.
    HAEMATOLOGICA, 2016, 101 : S98 - S98
  • [5] Standardized bone marrow assessment, risk variables, and survival in dogs with myelodysplastic syndrome and acute myeloid leukemia
    Meredith, Anna M.
    Beeler-Marfisi, Janet
    Berke, Olaf
    Mutsaers, Anthony J.
    Bienzle, Dorothee
    VETERINARY PATHOLOGY, 2025, 62 (01) : 64 - 73
  • [6] CXCL12 (SDF-1) and its truncation products in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) receiving ON 01910.Na (Rigosertib) in phase I trials
    Cho, Sool Y.
    Navada, Shyamala C.
    Silverman, Lewis R.
    Holland, James F.
    Roboz, John
    CANCER RESEARCH, 2012, 72
  • [7] Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia
    Kaszuba, Christina M.
    Rodems, Benjamin J.
    Sharma, Sonali
    Franco, Edgardo I.
    Ashton, John M.
    Calvi, Laura M.
    Bajaj, Jeevisha
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2023, (201):
  • [8] CORRELATION OF OVERALL SURVIVAL (OS) WITH BONE MARROW BLAST (BMBL) RESPONSE IN PATIENTS (PTS) WITH MYELODYSPLASTIC SYNDROMES (MDS)
    Silverman, L.
    Fenaux, P.
    Greenberg, P.
    Demakos, E.
    Santini, V.
    Seymour, J.
    Navada, S.
    Petrone, M.
    Snyder, B.
    Azarnia, N.
    Garcia-Manero, G.
    HAEMATOLOGICA, 2015, 100 : 242 - 242
  • [9] Impact of pre-transplant bone marrow blast percentage on survival in acute myeloid leukemia patients
    Ciftciler, Rafiye
    Goker, Hakan
    Buyukasik, Yahya
    Malkan, Umit Yavuz
    Saglam, Emine Arzu
    Demiroglu, Haluk
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (07): : 9288 - 9294
  • [10] Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS
    DeWitte, T
    VanBiezen, A
    Hermans, J
    Labopin, M
    Runde, V
    Or, R
    Meloni, G
    Mauri, SB
    Carella, A
    Apperley, J
    Gratwohl, A
    Laporte, JP
    BLOOD, 1997, 90 (10) : 3853 - 3857
12345